Shopping Cart 0
Cart Subtotal
AED 0

Global Blood Therapeutics Inc (GBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Global Blood Therapeutics Inc (GBT) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes novel oral medicines for the treatment of grievous blood-based disorders. The company's lead drug candidate GBT440 is an oral, small molecule drug for the treatment of sickle cell disease. Its GBT440 is a hemoglobin modifier which targets the mechanism of red blood cell sickling for the treatment of SCD. GBT's pipeline also includes an oral kallikrein inhibitor to prevent hereditary angioedema attacks. The company also develops therapies which are in preclinical and preliminary clinical stage for the treatment of for acute and chronic hypoxemic pulmonary disorders. It offers chemical and biological mechanisms of blood-based disorders. GBT is headquartered in South San Francisco, California, the US.

Global Blood Therapeutics Inc (GBT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Global Blood Therapeutics Raises USD48 Million in Series B Financing 11

Global Blood Therapeutics Raises USD 50 Million In Series A Financing 13

Partnerships 14

HitGen Enters into Research Agreement with Global Blood Therapeutics 14

Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 15

Licensing Agreements 16

Global Blood Therapeutics Enters into Licensing Agreement with Roche 16

Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 18

Equity Offering 19

Global Blood Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD248.4 Million 19

Global Blood Therapeutics Raises USD100 Million in Public Offering of Shares 21

Global Blood Therapeutics Raises USD143.8 Million in Public Offering of Shares 23

Global Blood Therapeutics Raises USD120 Million in Public Offering of Shares 25

Global Blood Therapeutics Raises USD138 Million in IPO of Shares 27

Global Blood Therapeutics Raises Funds through Private Placement of Shares 29

Acquisition 30

Novo Nordisk May Acquire Global Blood Therapeutics 30

Global Blood Therapeutics Inc-Key Competitors 31

Global Blood Therapeutics Inc-Key Employees 32

Global Blood Therapeutics Inc-Locations And Subsidiaries 33

Head Office 33

Recent Developments 34

Financial Announcements 34

Aug 02, 2018: Global Blood Therapeutics reports second quarter 2018 financial results 34

May 07, 2018: Global Blood Therapeutics Announces First Quarter 2018 Financial Results 36

Feb 27, 2018: GBT Reports Fourth Quarter and Year-End 2017 Financial Results 37

Nov 02, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results 38

Aug 07, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results 40

May 01, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results 42

Mar 13, 2017: Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results 43

Corporate Communications 45

Dec 22, 2017: GBT Appoints Wendy L. Yarno to Board of Directors 45

Product News 46

10/24/2017: Global Blood Therapeutics Announces Approval of First-in-Class Voxelotor as Nonproprietary Name for GBT440 46

10/11/2017: Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype 47

10/03/2017: Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October 49

02/14/2017: Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters 50

Product Approvals 51

Sep 05, 2017: Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease 51

Jun 28, 2017: Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD) 52

Clinical Trials 53

Oct 23, 2017: Global Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) Program 53

Jul 10, 2017: Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population 54

Jun 23, 2017: Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease 55

May 18, 2017: Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association's 22nd Congress 56

Feb 16, 2017: Global Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic Conditions 57

Jan 18, 2017: Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Global Blood Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Global Blood Therapeutics Raises USD48 Million in Series B Financing 11

Global Blood Therapeutics Raises USD 50 Million In Series A Financing 13

HitGen Enters into Research Agreement with Global Blood Therapeutics 14

Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 15

Global Blood Therapeutics Enters into Licensing Agreement with Roche 16

Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 18

Global Blood Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD248.4 Million 19

Global Blood Therapeutics Raises USD100 Million in Public Offering of Shares 21

Global Blood Therapeutics Raises USD143.8 Million in Public Offering of Shares 23

Global Blood Therapeutics Raises USD120 Million in Public Offering of Shares 25

Global Blood Therapeutics Raises USD138 Million in IPO of Shares 27

Global Blood Therapeutics Raises Funds through Private Placement of Shares 29

Novo Nordisk May Acquire Global Blood Therapeutics 30

Global Blood Therapeutics Inc, Key Competitors 31

Global Blood Therapeutics Inc, Key Employees 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Global Blood Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Global Blood Therapeutics Inc (GBT) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes novel oral medicines for the treatment of grievous blood-based disorders. The company's lead drug candidate GBT440 is an oral, small molecule drug for the treatment of sickle cell disease. Its GBT440 is a hemoglobin modifier which targets the mechanism of red blood cell sickling for the treatment of SCD. GBT's pipeline also includes an oral kallikrein inhibitor to prevent hereditary angioedema attacks. The company also develops therapies which are in preclinical and preliminary clinical stage for the treatment of for acute and chronic hypoxemic pulmonary disorders. It offers chemical and biological mechanisms of blood-based disorders. GBT is headquartered in South San Francisco, California, the US.

Global Blood Therapeutics Inc (GBT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Global Blood Therapeutics Raises USD48 Million in Series B Financing 11

Global Blood Therapeutics Raises USD 50 Million In Series A Financing 13

Partnerships 14

HitGen Enters into Research Agreement with Global Blood Therapeutics 14

Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 15

Licensing Agreements 16

Global Blood Therapeutics Enters into Licensing Agreement with Roche 16

Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 18

Equity Offering 19

Global Blood Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD248.4 Million 19

Global Blood Therapeutics Raises USD100 Million in Public Offering of Shares 21

Global Blood Therapeutics Raises USD143.8 Million in Public Offering of Shares 23

Global Blood Therapeutics Raises USD120 Million in Public Offering of Shares 25

Global Blood Therapeutics Raises USD138 Million in IPO of Shares 27

Global Blood Therapeutics Raises Funds through Private Placement of Shares 29

Acquisition 30

Novo Nordisk May Acquire Global Blood Therapeutics 30

Global Blood Therapeutics Inc-Key Competitors 31

Global Blood Therapeutics Inc-Key Employees 32

Global Blood Therapeutics Inc-Locations And Subsidiaries 33

Head Office 33

Recent Developments 34

Financial Announcements 34

Aug 02, 2018: Global Blood Therapeutics reports second quarter 2018 financial results 34

May 07, 2018: Global Blood Therapeutics Announces First Quarter 2018 Financial Results 36

Feb 27, 2018: GBT Reports Fourth Quarter and Year-End 2017 Financial Results 37

Nov 02, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results 38

Aug 07, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results 40

May 01, 2017: Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results 42

Mar 13, 2017: Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results 43

Corporate Communications 45

Dec 22, 2017: GBT Appoints Wendy L. Yarno to Board of Directors 45

Product News 46

10/24/2017: Global Blood Therapeutics Announces Approval of First-in-Class Voxelotor as Nonproprietary Name for GBT440 46

10/11/2017: Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype 47

10/03/2017: Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October 49

02/14/2017: Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters 50

Product Approvals 51

Sep 05, 2017: Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease 51

Jun 28, 2017: Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD) 52

Clinical Trials 53

Oct 23, 2017: Global Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) Program 53

Jul 10, 2017: Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population 54

Jun 23, 2017: Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease 55

May 18, 2017: Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association's 22nd Congress 56

Feb 16, 2017: Global Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic Conditions 57

Jan 18, 2017: Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Global Blood Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Global Blood Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Global Blood Therapeutics Raises USD48 Million in Series B Financing 11

Global Blood Therapeutics Raises USD 50 Million In Series A Financing 13

HitGen Enters into Research Agreement with Global Blood Therapeutics 14

Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 15

Global Blood Therapeutics Enters into Licensing Agreement with Roche 16

Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 18

Global Blood Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD248.4 Million 19

Global Blood Therapeutics Raises USD100 Million in Public Offering of Shares 21

Global Blood Therapeutics Raises USD143.8 Million in Public Offering of Shares 23

Global Blood Therapeutics Raises USD120 Million in Public Offering of Shares 25

Global Blood Therapeutics Raises USD138 Million in IPO of Shares 27

Global Blood Therapeutics Raises Funds through Private Placement of Shares 29

Novo Nordisk May Acquire Global Blood Therapeutics 30

Global Blood Therapeutics Inc, Key Competitors 31

Global Blood Therapeutics Inc, Key Employees 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Global Blood Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.